OncoMatch/Clinical Trials/NCT06522828

A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients

Is NCT06522828 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including SSGJ-707 and carboplatin for advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer.

Phase 2RecruitingSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.NCT06522828Data as of May 2026

Treatment: SSGJ-707 · carboplatin · paclitaxel — This is an open, multicenter Phase II clinical study of SSGJ-707 combined with chemotherapy in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer. The objective is to evaluate the safety, tolerability and antitumor activity of SSGJ-707 in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Ovarian Cancer

Endometrial Cancer

Performance status

ECOG 0–1(Restricted strenuous activity)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify